5 Key Takeaways
-
1
The 2025 ARVO Meeting presented data supporting the efficacy of OTX-TKI in treating nonproliferative diabetic retinopathy (NPDR).
-
2
The phase 1/2 HELIOS trial analyzed the effects of intravitreal axitinib hydrogel on macular fluid metrics in NPDR patients.
-
3
OTX-TKI-treated eyes showed greater reductions in mean retinal-RPE volume and central subfield thickness compared to sham over 48 weeks.
-
4
At week 48, OTX-TKI resulted in a mean retinal-RPE volume decrease of 0.92 mm³, while sham only decreased by 0.16 mm³.
-
5
The findings indicate that OTX-TKI may provide a long-lasting therapeutic option for NPDR, warranting further investigation.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.